Overlap of myasthenia gravis, myocarditis, and inflammatory myopathy secondary to immune checkpoint inhibitor (pembrolizumab) on a background of previously undiagnosed thymoma-associated acetylcholine receptor antibody-positive myasthenia gravis
Immune checkpoint inhibitors have been used successfully over the last several years for treatment of many types of advanced cancer. Those agents cause uncontrolled activation of the immune system frequently resulting in immune-related adverse effects and exacerbation of pre-existing autoimmune dise...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2025-04-01
|
| Series: | Нервно-мышечные болезни |
| Subjects: | |
| Online Access: | https://nmb.abvpress.ru/jour/article/view/649 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849400977186095104 |
|---|---|
| author | O. V. Finleyson |
| author_facet | O. V. Finleyson |
| author_sort | O. V. Finleyson |
| collection | DOAJ |
| description | Immune checkpoint inhibitors have been used successfully over the last several years for treatment of many types of advanced cancer. Those agents cause uncontrolled activation of the immune system frequently resulting in immune-related adverse effects and exacerbation of pre-existing autoimmune diseases. In particular, immune checkpoint inhibitors can cause myasthenia which is usually characterized by an acute onset, rapid progression, and frequent development of myasthenic crisis requiring mechanical ventilation. Coexistence of myasthenia with myocarditis and myositis was shown to be an unfavorable prognostic factor. Steroids, intravenous immunoglobulins, and plasmapheresis are used for treatment of immune checkpoint inhibitor- associated myasthenia. |
| format | Article |
| id | doaj-art-cff1a3b652b440199e16c8e7678476ee |
| institution | Kabale University |
| issn | 2222-8721 2413-0443 |
| language | Russian |
| publishDate | 2025-04-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Нервно-мышечные болезни |
| spelling | doaj-art-cff1a3b652b440199e16c8e7678476ee2025-08-20T03:37:52ZrusABV-pressНервно-мышечные болезни2222-87212413-04432025-04-01151616610.17650/2222-8721-2025-15-1-61-66409Overlap of myasthenia gravis, myocarditis, and inflammatory myopathy secondary to immune checkpoint inhibitor (pembrolizumab) on a background of previously undiagnosed thymoma-associated acetylcholine receptor antibody-positive myasthenia gravisO. V. Finleyson0Hospital “Mackenzie Health”Immune checkpoint inhibitors have been used successfully over the last several years for treatment of many types of advanced cancer. Those agents cause uncontrolled activation of the immune system frequently resulting in immune-related adverse effects and exacerbation of pre-existing autoimmune diseases. In particular, immune checkpoint inhibitors can cause myasthenia which is usually characterized by an acute onset, rapid progression, and frequent development of myasthenic crisis requiring mechanical ventilation. Coexistence of myasthenia with myocarditis and myositis was shown to be an unfavorable prognostic factor. Steroids, intravenous immunoglobulins, and plasmapheresis are used for treatment of immune checkpoint inhibitor- associated myasthenia.https://nmb.abvpress.ru/jour/article/view/649myasthenia gravesmyocarditismyositisimmune checkpoint inhibitorsthymomaimmune-related adverse effects |
| spellingShingle | O. V. Finleyson Overlap of myasthenia gravis, myocarditis, and inflammatory myopathy secondary to immune checkpoint inhibitor (pembrolizumab) on a background of previously undiagnosed thymoma-associated acetylcholine receptor antibody-positive myasthenia gravis Нервно-мышечные болезни myasthenia graves myocarditis myositis immune checkpoint inhibitors thymoma immune-related adverse effects |
| title | Overlap of myasthenia gravis, myocarditis, and inflammatory myopathy secondary to immune checkpoint inhibitor (pembrolizumab) on a background of previously undiagnosed thymoma-associated acetylcholine receptor antibody-positive myasthenia gravis |
| title_full | Overlap of myasthenia gravis, myocarditis, and inflammatory myopathy secondary to immune checkpoint inhibitor (pembrolizumab) on a background of previously undiagnosed thymoma-associated acetylcholine receptor antibody-positive myasthenia gravis |
| title_fullStr | Overlap of myasthenia gravis, myocarditis, and inflammatory myopathy secondary to immune checkpoint inhibitor (pembrolizumab) on a background of previously undiagnosed thymoma-associated acetylcholine receptor antibody-positive myasthenia gravis |
| title_full_unstemmed | Overlap of myasthenia gravis, myocarditis, and inflammatory myopathy secondary to immune checkpoint inhibitor (pembrolizumab) on a background of previously undiagnosed thymoma-associated acetylcholine receptor antibody-positive myasthenia gravis |
| title_short | Overlap of myasthenia gravis, myocarditis, and inflammatory myopathy secondary to immune checkpoint inhibitor (pembrolizumab) on a background of previously undiagnosed thymoma-associated acetylcholine receptor antibody-positive myasthenia gravis |
| title_sort | overlap of myasthenia gravis myocarditis and inflammatory myopathy secondary to immune checkpoint inhibitor pembrolizumab on a background of previously undiagnosed thymoma associated acetylcholine receptor antibody positive myasthenia gravis |
| topic | myasthenia graves myocarditis myositis immune checkpoint inhibitors thymoma immune-related adverse effects |
| url | https://nmb.abvpress.ru/jour/article/view/649 |
| work_keys_str_mv | AT ovfinleyson overlapofmyastheniagravismyocarditisandinflammatorymyopathysecondarytoimmunecheckpointinhibitorpembrolizumabonabackgroundofpreviouslyundiagnosedthymomaassociatedacetylcholinereceptorantibodypositivemyastheniagravis |